{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:45:39Z","timestamp":1761540339443,"version":"3.30.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2001,4,1]]},"DOI":"10.1038\/sj.bmt.1703005","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T15:51:24Z","timestamp":1031154684000},"page":"847-853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support"],"prefix":"10.1038","volume":"27","author":[{"given":"M","family":"Bewick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AM","family":"Parissenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Gl\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RM","family":"Lafrenie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2001,7,26]]},"reference":[{"key":"BF1703005_CR1","first-page":"pp 131","volume-title":"Molecular Basis of Oncology","author":"D Yu","year":"1995","unstructured":"Yu D, Hung M-C . HER-2\/neu gene in human cancers. In: Freireich E, Stass SA (eds) Molecular Basis of Oncology vol. 5: Blackwell Scientific: Cambridge 1995 pp 131\u2013162"},{"key":"BF1703005_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene Science 1987 235: 177\u2013182","journal-title":"Science"},{"key":"BF1703005_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2 \/neu proto-oncogene in human breast and ovarian cancer Science 1989 244: 707\u2013712","journal-title":"Science"},{"key":"BF1703005_CR4","first-page":"Abstr. 274","volume":"19","author":"A Lipton","year":"2000","unstructured":"Lipton A, Ali SM, Leitzel K et al. Elevated serum HER-2\/neu level predicts decrease response to hormone therapy in metastatic breast cancer Proc Am Soc Clin Oncol 2000 19: Abstr. 274","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1703005_CR5","first-page":"Abstr. 300","volume":"19","author":"M De Laurentiis","year":"2000","unstructured":"De Laurentiis M, Arpino G, Massarelli E et al. A metanalysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC) Proc Am Soc Clin Oncol 2000 19: Abstr. 300","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1703005_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/stem.160413","volume":"16","author":"JS Ross","year":"1998","unstructured":"Ross JS, Fletcher J . The HER-2\/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy Stem Cells 1998 16: 413\u2013428","journal-title":"Stem Cells"},{"key":"BF1703005_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/sj.bmt.1701907","volume":"24","author":"M Bewick","year":"1999","unstructured":"Bewick M, Chadderton T, Conlon M et al. Expression of C-erbB-2\/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support Bone Marrow Transplant 1999 24: 377\u2013384.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703005_CR8","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1200\/JCO.2000.18.10.2070","volume":"18","author":"Y Nieto","year":"2000","unstructured":"Nieto Y, Cagnoni PJ, Nawaz S et al. Evaluation of the predictive value of Her-2\/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high dose chemotherapy and autologous stem cell transplantation J Clin Oncol 2000 18: 2070\u20132080","journal-title":"J Clin Oncol"},{"key":"BF1703005_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/00000421-200004000-00006","volume":"23","author":"V Ferraresi","year":"2000","unstructured":"Ferraresi V, Milella M, Vaccaro A et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study Am J Clin Oncol 2000 23: 132\u2013139","journal-title":"Am J Clin Oncol"},{"key":"BF1703005_CR10","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1863::AID-CNCR15>3.0.CO;2-E","volume":"88","author":"AG Maiche","year":"2000","unstructured":"Maiche AG, Jekunen AP, Kaleva-Kerola J, Blanco-Sequeiros G . High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma Cancer 2000 88: 1863\u20131868","journal-title":"Cancer"},{"key":"BF1703005_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/028418600430969","volume":"39","author":"HT Greinix","year":"2000","unstructured":"Greinix HT, Linkesch W, Seifert M et al. Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients Acta Oncol 2000 39: 47\u201352","journal-title":"Acta Oncol"},{"key":"BF1703005_CR12","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","volume":"18","author":"HJ Burstein","year":"2000","unstructured":"Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 2000 18: 1212\u20131219","journal-title":"J Clin Oncol"},{"key":"BF1703005_CR13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0959-8049(97)10168-X","volume":"34","author":"S Gluck","year":"1998","unstructured":"Gluck S, Germond C, Lopez P et al. High-dose paclitaxel, cyclophosphamide and mitoxantrone followed by autologous blood stem cell support for the treatment of metastatic breast cancer: a phase I trial Eur J Cancer 1998 34: 1008\u20131014","journal-title":"Eur J Cancer"},{"key":"BF1703005_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"BF1703005_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life-tables (with discussion) J Roy Stat Soc Ser B, 1972 34: 187\u2013220","journal-title":"J Roy Stat Soc Ser B"},{"key":"BF1703005_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/jnci\/90.18.1361","volume":"90","author":"S Paik","year":"1998","unstructured":"Paik S, Bryant J, Park C et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor negative breast cancer J Natl Can Inst 1998 90: 1361\u20131370","journal-title":"J Natl Can Inst"},{"key":"BF1703005_CR17","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","volume":"330","author":"HB Muss","year":"1994","unstructured":"Muss HB, Thor AD, Berry DA et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer New Engl J Med 1994 330: 1260\u20131266","journal-title":"New Engl J Med"},{"key":"BF1703005_CR18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","volume":"14","author":"PA Greenberg","year":"1996","unstructured":"Greenberg PA, Hortobagyi GN, Smith TL et al. Long term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 1996 14: 2197\u20132205","journal-title":"J Clin Oncol"},{"key":"BF1703005_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJM200004133421501","volume":"342","author":"E Stadtmauer","year":"2000","unstructured":"Stadtmauer E, O'Neill A, Goldstein L et al. Conventional dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer New Engl J Med 2000 342: 1069\u20131076","journal-title":"New Engl J Med"},{"key":"BF1703005_CR20","first-page":"(Abstr. 176)","volume":"15","author":"JH Doroshow","year":"1996","unstructured":"Doroshow JH, Simpson J, Somlo G et al. Immunohistochemical and histopathologic factors predicting progression-free survival (PFS) and overall survival (OS) following high dose chemotherapy (HDCT) and stem cell rescue (SCR) for responsive metastatic breast cancer Proc Am Soc Clin Oncol 1996 15: (Abstr. 176)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1703005_CR21","first-page":"Abstr. 280","volume":"19","author":"HJ Luck","year":"2000","unstructured":"Luck HJ, Thomssen C, Untch M et al. Multicentric phase III study in first line treatment of advanced metastatic breastcancer (ABO). Epirubicin\/paclitaxel (ET) vs epirubicin\/cyclophosphamide (EC). A study of the AGO breast cancer group Proc Am Soc Clin Oncol 2000 19: Abstr. 280","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1703005_CR22","first-page":"43","volume":"11","author":"J Baselga","year":"1997","unstructured":"Baselga J, Seidman AD, Rosen PP, Norton L . Her2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications Oncology 1997 11: 43\u201348","journal-title":"Oncology"},{"key":"BF1703005_CR23","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/bjc.1998.377","volume":"77","author":"T J\u00e4rvinen","year":"1998","unstructured":"J\u00e4rvinen T, Holli K, Kuukasjarvi T, Isola JJ . Predictive value of topoisomerase II and other prognostic factors for epirubicin chemotherapy in advanced breast cancer Br J Cancer 1998 77: 2267\u20132273","journal-title":"Br J Cancer"},{"key":"BF1703005_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A","volume":"22","author":"D Yu","year":"2000","unstructured":"Yu D, Hung M-C . Role of erbB2 in breast cancer chemosensitivity Bioessays 2000 22: 673\u2013680","journal-title":"Bioessays"},{"key":"BF1703005_CR25","first-page":"Abstr. 319","volume":"19","author":"AD Seidman","year":"2000","unstructured":"Seidman AD, Fornier M, Esteva F et al. Final report: weekly (W) herceptin (H) and taxol (T) for metastatic breast cancer (MBC): analysis of efficacy by HER2 immunophenotype (immunohistochemistry [IHC]) and gene amplification (fluorescent in situ hybridization) Proc Am Soc Clin Oncol 2000 19: Abstr. 319","journal-title":"Proc Am Soc Clin Oncol"},{"unstructured":"Wong WL, Bajamonde A, Nelson B et al. Baseline serum HER2 (sHER2) levels in the pivotal herceptin breast cancer trials: a comparison of 2 ELISA methods Proc Am Soc Clin Oncol 2000 Abstr. 297","key":"BF1703005_CR26"},{"key":"BF1703005_CR27","first-page":"2356","volume":"6","author":"R Colomer","year":"2000","unstructured":"Colomer R, Monero S, Lluch A et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer Clin Cancer Res 2000 6: 2356\u20132362","journal-title":"Clin Cancer Res"},{"key":"BF1703005_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/oxfordjournals.annonc.a058593","volume":"4","author":"R Kath","year":"1993","unstructured":"Kath R, Hoffken K, Otte C et al. The neu-oncoene product in serum and tissue of patients with breast carcinoma Ann Oncol 1993 4: 585\u2013590","journal-title":"Ann Oncol"},{"key":"BF1703005_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/A:1005734429304","volume":"51","author":"R Molina","year":"1998","unstructured":"Molina R, Jo J, Filella X et al. C-erbB-2 oncoprotein, CEA, and CA 15\u20133 in patients with breast cancer: prognostic value Breast Cancer Res Treat 1998 51: 109\u2013119","journal-title":"Breast Cancer Res Treat"},{"key":"BF1703005_CR30","first-page":"S53-S67","volume":"112","author":"JS Ross","year":"1999","unstructured":"Ross JS, Fletcher JA . HER-2\/neu (c-erbB-2) gene and protein in breast cancer Am J Clin Pathol 1999 112: (Suppl. 1) S53-S67","journal-title":"Am J Clin Pathol"},{"key":"BF1703005_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/(SICI)1097-0215(19960822)69:4<273::AID-IJC6>3.0.CO;2-U","volume":"69","author":"U Lonn","year":"1996","unstructured":"Lonn U, Lonn S, Ingelmann-Sundberg H et al. c-erbB-2\/int-2 amplification appears faster in breast cancer patients receiving second-line endocrine treatment Int J Cancer 1996 69: 273\u2013277","journal-title":"Int J Cancer"},{"key":"BF1703005_CR32","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/1097-0142(19940201)73:3<652::AID-CNCR2820730324>3.0.CO;2-4","volume":"73","author":"JJ Isola","year":"1994","unstructured":"Isola JJ, Holli K, Oksa H et al. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer Cancer 1994 73: 652\u2013658","journal-title":"Cancer"},{"key":"BF1703005_CR33","first-page":"2363","volume":"6","author":"C Streckfus","year":"2000","unstructured":"Streckfus C, Bigler L, Dellinger T et al. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study Clin Can Res 2000 6: 2363\u20132370","journal-title":"Clin Can Res"},{"unstructured":"Gluck S, Crump M . A randomized trial of high-dose chemotherapy and autologous stem cell therapy versus standard therapy in women with metastatic breast cancer who have responded to anthracycline or taxane-based induction chemotherapy National Cancer Institute of Canada Clinical Trials Group, NCIC CTG Protocol 1997 16","key":"BF1703005_CR34"},{"key":"BF1703005_CR35","first-page":"2a","volume":"18","author":"WP Peters","year":"1999","unstructured":"Peters WP, Rosner G, Vredenburgh J et al. A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082\/SWOG 9114\/NCIC-MA-13 Proc Am Soc Clin Oncol 1999 18: 2a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1703005_CR36","first-page":"Abstr. 286","volume":"19","author":"S Rodenhuis","year":"2000","unstructured":"Rodenhuis S, Botenbal M, Beex L et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes Proc Am Soc Clin Oncol 2000 19: Abstr. 286","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703005","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T11:05:00Z","timestamp":1733569500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,4,1]]}},"alternative-id":["BF1703005"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703005","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2001,4,1]]},"assertion":[{"value":"7 November 2000","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2001","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}